Cholangiocarcinoma: Epidemiology and global management

被引:3
作者
Dreyer, C. [1 ]
Le Tourneau, C. [1 ]
Faivre, S. [1 ]
Qlan, Z. [2 ]
Degos, F. [2 ]
Vullierme, M. -P. [3 ]
Paradis, V. [6 ]
Hammel, P. [4 ]
Rusznlewski, P. [4 ]
Cortes, A. [5 ]
Farges, O. [5 ]
Belghiti, J.
Valla, D. [2 ,6 ]
Raymond, E. [1 ]
机构
[1] Hop Beaujon, Serv Interhosp Cancerol Bichat Beaujon, F-92118 Clichy, France
[2] Hop Beaujon, Serv Hepatol, F-92118 Clichy, France
[3] Hop Beaujon, Serv Radiol, F-92118 Clichy, France
[4] Hop Beaujon, Serv Gastroenterol, F-92118 Clichy, France
[5] Hop Beaujon, Serv Chirurg Viscerale, F-92118 Clichy, France
[6] Hop Beaujon, Serv Anatomopathol, F-92118 Clichy, France
来源
REVUE DE MEDECINE INTERNE | 2008年 / 29卷 / 08期
关键词
intrahepatic; extrahepatic and gallbladder cholangiocarcinoma; epidemiology; prognostic factors;
D O I
10.1016/j.revmed.2007.11.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Scope. - Cholangiocarcinoma. or biliary tract tumors, are Fare tumors for which Survival is short, Lis diagnosis is often made at an advanced stage. Indeed, diagnosis remains difficult, since symptoms are often unspecific and appear at latest stages. This article presents an update of recent data and therapeutic options. Current situation and salient points. - Several etiologic factors have been identified, but for most patients, none of these factors can be found. Prognosis is often poor, and remains difficult to establish because of the lack of sufficient large-scale studies looking at the impact on preexisting tumor characteristics on overall survival. Surgery remains when possible the gold standard. When tumor removal is impossible, due to a local extension, the appropriate care of patients remains to be defined. Chemotherapy has been proposed with evidence of objective response but limited data on its ability to prolong overall survival and to enhance quality of life. Active chemotherapies appear to be made from combination of an antimetabolite, such as 5-fluorouracile or gemcitabine, and a platinum drug. Perspectives. - In the near future, indications of chemotherapy could be enlarged and targeted therapy might also be used, since several molecules have been tested in preclinical Studies, and be offered to patients in clinical trials. (C) 2007 Elsevier Masson SAS. Tous droits reserves.
引用
收藏
页码:642 / 651
页数:10
相关论文
共 56 条
  • [1] Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma:: a GERCOR study
    André, T
    Tournigand, C
    Rosmorduc, O
    Provent, S
    Maindrault-Goebel, F
    Avenin, D
    Selle, F
    Paye, F
    Hannoun, L
    Houry, S
    Gayet, B
    Lotz, JP
    de Gramont, A
    Louvet, C
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (09) : 1339 - 1343
  • [2] ARETXABALA X, 1999, AM SURGEON, V65, P241
  • [3] Medical management of cholangiocarcinoma
    Barrioz, T
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (01): : 57 - 65
  • [4] Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours
    Berman, DM
    Karhadkar, SS
    Maitra, A
    de Oca, RM
    Gerstenblith, MR
    Briggs, K
    Parker, AR
    Shimada, Y
    Eshleman, JR
    Watkins, DN
    Beachy, PA
    [J]. NATURE, 2003, 425 (6960) : 846 - 851
  • [5] Incidence of gastrointestinal cancers in France
    Bouvier, AM
    Remontet, L
    Jougla, E
    Launoy, G
    Grosclaude, P
    Buémi, A
    Tretarre, B
    Velten, M
    Dancourt, V
    Menegoz, FO
    Guizard, AV
    Lesec'h, JM
    Peng, J
    Bercelli, P
    Arveux, P
    Estève, J
    Faivre, J
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (10): : 877 - 881
  • [6] Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis
    Broome, U
    Olsson, R
    Loof, L
    Bodemar, G
    Hultcrantz, R
    Danielsson, A
    Prytz, H
    SandbergGertzen, H
    Wallerstedt, S
    Lindberg, G
    [J]. GUT, 1996, 38 (04) : 610 - 615
  • [7] Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma
    Cantore, M
    Rabbi, C
    Guadagni, S
    Zamagni, D
    Aitini, E
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (10) : 1687 - 1688
  • [8] CARRIAGA MT, 1995, CANCER-AM CANCER SOC, V75, P171, DOI 10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO
  • [9] 2-2
  • [10] Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells
    Chiorean, MV
    Guicciardi, ME
    Yoon, JH
    Bronk, SF
    Kaufmanns, SH
    Gores, GJ
    [J]. LIVER INTERNATIONAL, 2004, 24 (06) : 687 - 695